Company intelligence / Profile preview

ITBMed

Stockholm, Sweden

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Siplizumab has demonstrated the potential to allow organ transplant patients to discontinue all immunosuppressive drugs post-transplantation. In phase II trials it enabled successful transplants without lifelong immunosuppression. Recent phase II trials have been completed in renal transplantation with positive results reported as of December 2024.

Therapeutic areas: NeurologyEndocrinologyImmunologyNephrology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

siplizumab

Beyond the preview

Go deeper on ITBMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITBMed.

Explore the full profile